By Fineline Cube Astellas Pharma Inc. (TYO: 4503) announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab (Keytruda) as a first‑line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are Claudin 18.2 (CLDN18.2)-positive and HER2-negative. The milestone advances one of Astellas’s lead bispecific candidates in a molecularly defined gastric cancer population with a growing competitive landscape.
Study Design Snapshot
| Element | Detail |
|---|---|
| Sponsor | Astellas Pharma Inc. (TYO: 4503) |
| Asset | ASP2138, investigational bispecific antibody |
| Phase | Phase 3 (first patient dosed) |
| Regimen | ASP2138 + chemotherapy + pembrolizumab (Keytruda) |
| Setting | First‑line, locally advanced unresectable or metastatic |
| Population | Adults with gastric or gastroesophageal junction (GEJ) adenocarcinoma, CLDN18.2-positive, HER2-negative |
| Milestone Date | 25 Aug 2026 |
Drug Profile & Mechanism of Action
- Molecule: ASP2138, an investigational bispecific antibody
- Route: Subcutaneous administration, a convenience differentiator versus intravenous formats
- Targets: CLDN18.2, a protein expressed on certain tumor cells, and CD3 on T cells
- Mechanism: By binding both targets, ASP2138 brings CD3‑positive T cells closer to CLDN18.2‑expressing tumor cells and activates their anti‑tumor response
- Partner Agent: Combined with standard chemotherapy and pembrolizumab (Keytruda), a backbone regimen in first‑line gastric/GEJ cancer
- Biomarker Strategy: Restriction to CLDN18.2-positive, HER2-negative tumors aligns ASP2138 with the precision‑oncology segmentation reshaping first‑line gastric cancer care
Clinical Evidence – Phase 3 Program
- The study marks the first patient dosed in Astellas’s registrational‑intent Phase 3 evaluation of ASP2138 in this biomarker‑selected first‑line setting.
- The CLDN18.2-positive, HER2-negative population is clinically distinct from HER2-positive disease, where separate targeted regimens apply, underscoring the trial’s focus on a defined segment of gastric/GEJ adenocarcinoma.
- Combining a subcutaneous T‑cell‑engaging bispecific with chemo‑immunotherapy aims to improve upon current first‑line standards while maintaining manageable administration for patients.
Market Impact & Outlook
- Large First‑Line Opportunity: Gastric and GEJ adenocarcinoma remain among the leading causes of cancer mortality globally, and first‑line combination regimens anchor both clinical practice and commercial value in this space.
- CLDN18.2 as a Hot Target: The CLDN18.2 arena has become one of oncology’s most contested frontiers, with multiple antibodies, bispecifics, and ADCs in development; biomarker‑selected, chemo‑immunotherapy‑combined data will be key to differentiation.
- Subcutaneous Convenience: Subcutaneous dosing could offer a meaningful administration advantage over intravenous competitors in routine clinical practice if efficacy supports it.
- Watch Items: Enrollment pace, interim safety and efficacy readouts, and positioning against other CLDN18.2‑targeted agents advancing in first‑line gastric cancer.
Forward‑Looking Statements – This brief is for informational purposes only and does not constitute investment, medical, or regulatory advice. Statements regarding ongoing clinical development and future commercialization are forward‑looking and subject to risks and uncertainties; actual results may differ materially. Refer to official announcements from Astellas Pharma and clinical trial registries for authoritative details.-Fineline Info & Tech